IL280234A - Antibodies against Campylobacter species - Google Patents

Antibodies against Campylobacter species

Info

Publication number
IL280234A
IL280234A IL280234A IL28023421A IL280234A IL 280234 A IL280234 A IL 280234A IL 280234 A IL280234 A IL 280234A IL 28023421 A IL28023421 A IL 28023421A IL 280234 A IL280234 A IL 280234A
Authority
IL
Israel
Prior art keywords
antibodies against
campylobacter species
against campylobacter
species
antibodies
Prior art date
Application number
IL280234A
Other languages
English (en)
Hebrew (he)
Inventor
PIZZUTO Matteo
Benigni Fabio
Corti Davide
Grassi Fabio
Perruzza Lisa
Original Assignee
Humabs Biomed Sa
Inst Res Biomedicine
PIZZUTO Matteo
Benigni Fabio
Corti Davide
Grassi Fabio
Perruzza Lisa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa, Inst Res Biomedicine, PIZZUTO Matteo, Benigni Fabio, Corti Davide, Grassi Fabio, Perruzza Lisa filed Critical Humabs Biomed Sa
Publication of IL280234A publication Critical patent/IL280234A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/121—Helicobacter (G); Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL280234A 2018-07-17 2021-01-17 Antibodies against Campylobacter species IL280234A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862699573P 2018-07-17 2018-07-17
PCT/US2019/042070 WO2020018584A2 (en) 2018-07-17 2019-07-16 Antibodies against campylobacter species

Publications (1)

Publication Number Publication Date
IL280234A true IL280234A (en) 2021-03-25

Family

ID=67480448

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280234A IL280234A (en) 2018-07-17 2021-01-17 Antibodies against Campylobacter species

Country Status (13)

Country Link
US (1) US12297258B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823727A2 (cg-RX-API-DMAC7.html)
JP (2) JP2021530237A (cg-RX-API-DMAC7.html)
KR (1) KR20210041557A (cg-RX-API-DMAC7.html)
CN (1) CN112867541B (cg-RX-API-DMAC7.html)
AU (1) AU2019306543A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021000772A2 (cg-RX-API-DMAC7.html)
CA (1) CA3105222A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190194A1 (cg-RX-API-DMAC7.html)
IL (1) IL280234A (cg-RX-API-DMAC7.html)
MX (1) MX2021000268A (cg-RX-API-DMAC7.html)
SG (1) SG11202013193XA (cg-RX-API-DMAC7.html)
WO (1) WO2020018584A2 (cg-RX-API-DMAC7.html)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
WO2005028515A1 (ja) 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. ヒトインスリン様成長因子に対する遺伝子組換え抗体
ES2358804T3 (es) * 2003-11-21 2011-05-13 Ace Biosciences A/S Polipéptidos de campylobacter jejuni ubicados en superficie.
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
MX2015005304A (es) 2012-10-24 2016-04-04 Nat Res Council Canada Anticuerpo contra campylobacter jejuni y usos para los mismos.
EP2995679A4 (en) 2013-03-11 2016-12-14 Kansai Bunri Sogo Gakuen PROCESS FOR PREPARING MONOCLONAL IGA ANTIBODIES

Also Published As

Publication number Publication date
EA202190194A1 (ru) 2021-04-16
MX2021000268A (es) 2021-06-08
EP3823727A2 (en) 2021-05-26
US12297258B2 (en) 2025-05-13
JP2024116266A (ja) 2024-08-27
KR20210041557A (ko) 2021-04-15
WO2020018584A2 (en) 2020-01-23
WO2020018584A3 (en) 2020-04-02
SG11202013193XA (en) 2021-02-25
US20210284718A1 (en) 2021-09-16
CA3105222A1 (en) 2020-01-23
CN112867541B (zh) 2024-08-30
AU2019306543A1 (en) 2021-01-28
CN112867541A (zh) 2021-05-28
BR112021000772A2 (pt) 2021-04-13
JP2021530237A (ja) 2021-11-11

Similar Documents

Publication Publication Date Title
IL280780A (en) Anti-TIGIT antibodies
IL279321A (en) Anti-SIRPalpha antibody
IL280013A (en) Anti-IL36R antibodies
IL279352A (en) IL-11RA antibodies
IL291068A (en) Anti-cd73 antibodies
IL289112A (en) Antibodies against tigit
IL278010A (en) Antibodies to galectin 10
SG11202013138RA (en) Anti-steap1 antigen-binding protein
GB201905150D0 (en) Ant-ige antibodies
IL277030A (en) Antibodies
SG11202106171WA (en) Anti-btla antibodies
GB201817172D0 (en) Antibody
ZA202101177B (en) Anti-btla antibody
GB201811368D0 (en) Antibody
IL284584A (en) Anti-tigit antibodies
GB2581174B (en) Antibodies against hEPCR
SG11202102114UA (en) Anti-klrg1 antibodies
GB201917480D0 (en) Antibodies
GB201900732D0 (en) Antibodies
GB201806084D0 (en) Antibodies
IL268489A (en) oboe
IL289160A (en) Anti-angpt2 antibodies
PL4025612T3 (pl) Przeciwciała anty-fukozylo-gm1
GB2598698B (en) Affinity-maturated anti-ASICIa antibodies
SG11202013193XA (en) Antibodies against campylobacter species